Selenium is a constituent of proteins of several classes. Selenium-containing proteins generally fall into three categories [4,5]. One of these classes includes those proteins containing selenomethionine in which selenium, due to its structural similarity to sulfur, incorporates non-specifically into the sulfur-containing amino acid [6]. The most common and best studied class of selenium-containing proteins includes those that contain the amino acid selenocysteine (Sec). Throughout evolution, from bacteria to humans, Sec is incorporated co-translationally by its insertion in response to UGA codons that otherwise would serve at translational termination signals. In eukaryotes, the recognition of UGA as Sec requires a regulatory sequence, called a SECIS element, in the 3′-untranslated region of the selenoprotein mRNA [7]. All in-frame UGA codons contained in a SECIS-including mRNA are recognized as encoding Sec, which is incorporated into the elongating peptide by a unique translational machinery that includes a highly unusual tRNA, an elongation factor as well as other proteins required for selenoprotein synthesis [2,8]. There are 25 human Sec-containing selenoprotein genes and 24 in the mouse [5]. The best studied Sec-containing protein is the ubiquitously expressed glutathione peroxidase-1 (GPx1). This enzyme uses reducing equivalents from glutathione to detoxify lipid and hydrogen...
peroxides and its levels are sensitive to selenium availability. Changes in the levels of GPx1 have been associated with a variety of human diseases. The loss of one GPx1 allele has been frequently observed during the development of several common cancer types, including those of the breast, lung and colon as well as those of the head and neck [9]. An additional class of selenium-binding proteins includes those proteins in which selenium is bound to the peptide, but not incorporated into an amino acid as Sec. One such protein is the selenium-binding protein 1 (SBP1) [10].

Identification and biological functions of SBP1

The human selenium-binding protein gene (SBP1, SELENBP1 or hSP56) was first cloned in 1997 [11] and has been suggested to mediate the intracellular transport of selenium [11,12], although evidence for this role has not yet been provided. SBP1 is located on chromosome 1 at q21–22, and is the homologue of the mouse SP56 gene that was originally reported as a 56 kDa mouse protein that stably bound 75selenium [10]. The human cDNA contains a 472 amino acid encoding open reading frame [11]. Chen et al. has detected two 56 kD SBP1 isoforms in human lung cancers using Tandem mass spectrometry and 2-D western blot analysis, in which an acidic isoform (457AA) was observed at lower levels in lung adenocarcinomas compared with normal lung, with two additional, more acidic SBP1 isoforms only observed in normal lung tissue [13].

The SBP1 protein has been detected in both the nucleus and cytoplasm, as assayed by immunohistochemical staining [13,14] and it is expressed in a variety of tissue types, including the heart, lung, kidney and tissues of the digestive tract. SBP1 is well conserved in eukaryotic evolution, with a BLAST search revealing a better than 65% identity between the human gene and that of organisms as diverse fish, birds, urchins and Chlamys farreri, a bivalve (unpublished observation). The form of selenium in SBP1 is unknown as is the nature of its association: the selenium remains bound to the protein when electrophoresed in SDS acrylamine gels but dissociates at extremes of pH [10].

The function of SBP1 is unknown although it may be involved in intra-golgi transport [12]. Recently, SBP1 has been shown to be a target of the hypoxia-inducible factor-1 alpha (HIF1α) [15] and to directly interact with von Hippel-Lindau protein (pVHL) which may play a role in the proteasomal degradation pathway in a selenium dependent manner [16]. SBP1 has also been proposed to serve as a marker in colonic cell differentiation [14].

Lower SBP1 levels in cancer are associated with poor clinical cancer prognosis

Interest in SBP1 as a prognostic indicator was stimulated in 2004 when gene expression profiling for predictors of outcome in the management of pleural mesothelioma indicated that SBP1 was among a group of 27 genes whose expression segregated “good risk” from “bad risk” post-surgery in mesothelioma patients [17]. Subsequently, significantly reduced levels of SBP1 in tumors as compared to the corresponding normal tissue has now been documented in cancers of the ovary, lung, esophagus, colon, stomach, liver and in uterine leiomyoma [13,14,18-27]. Reduced expression of SBP1 is also associated with tumor progression. SBP1 levels are reduced in Barrett’s esophagus (BE), BE with low-grade dysplasia, BE with high-grade dysplasia, and are significantly reduced in esophageal adenocarcinoma [21]. Similarly, lower levels of SBP1 are gradually reduced with gastric cancer progression [24]. In lung adenocarcinoma, SBP1 protein isoforms and mRNA levels were significantly decreased in poorly differentiated adenocarcinoma compared to the moderately- and well-differentiated adenocarcinomas [13]. Lower levels of SBP1 were also associated with the late stages of colorectal [14,19] and lung cancer (T2-T4 versus T1) [13].

Several clinical studies have provided evidence indicating that lower SBP1 levels are associated with worse prognosis of the cancers of lung, colorectal, stomach, and liver [13,14,19,22,23,26,27]. Our studies have demonstrated an association between SBP1 expression, as assayed by tissue microarray (TMA), with disease-free survival as well as overall survival among stage III colorectal cancer patients using Kaplan–Meier analysis [14]. The conclusions drawn in this study have been supported by the work of others. Chen et al. reported that low levels of the native form SBP1 protein (460aa) was significantly correlated with poor survival among patients with lung cancer [13]. More recently, Huang et al. presented data that SBP1 was an independent risk factor for overall survival and disease recurrence; patients with lower SBP1 expression as determined using tumor microarrays experienced shorter overall survival periods and higher rates of disease recurrence [26]. While the expression or alterations of SBP1 in gastrointestinal stromal tumors (GISTs) remains unknown although many advances and management have been made [28,29].

Reduced levels of SBP1 are associated with epigenetic changes

We have previously reported that SBP1 protein and mRNA expression were dramatically lower in human colorectal cancer [14] and recent studies have indicated an association between epigenetic changes of SBP1 and its reduced expression. Our group has provided data indicating that reduced SBP1 expression was linked to the hypermethylation in the SBP1 promoter using methylation analysis; SBP1 promoter methylation in cancer tissues was much higher than those in the adjacent normal mucosa [20]. These data clearly demonstrate that SBP1 promoter methylation may be one of the mechanisms
responsible for SBP1 downregulation in human colon cancers. Similar results were observed in human colorectal cancer cell lines including HCT116, SW620, SW480, HT29 and Caco2 cells in which lower or undetectable SBP1 levels were strongly associated with SBP1 promoter hypermethylation. In addition, SBP1 promoter hypermethylation led to reduced SBP1 promoter transcriptional activity in vitro [20]. Treatment with 5′-Aza-2′-Deoxycytidine (Decitabine, DAC) reversed SBP1 promoter methylation and stimulated its expression in human colorectal cancer cells [20].

Epigenetic changes in SBP1 were also observed during esophageal carcinogenesis where the proximal regions of the SBP1 promoter was hypermethylated during the progression of Barrett’s esophagus to adenocarcinoma as well as in esophageal cancer cell lines [21]. In addition, posttranscriptional mechanisms, such as the appearance of isoforms resulting from differential splicing, seemed to modulate SBP1 protein levels, as did single nucleotide polymorphisms (SNPs) [21]. As in the case of colon-derived cell lines, the inhibition of methylation could restore partial expression of SBP1 in esophageal cancer cell lines [21]. In contrast, the treatment of A549 lung adenocarcinoma cells with the methylation inhibitor 5-azacytidine did not affect SBP1 expression [13].

SBP1 as a putative tumor suppressor
Several lines of evidences have provided support for a tumor suppressor role of SBP1. Analysis of tumor proliferation status using the Ki-67 proliferation marker indicated that down-regulated expression of SBP1 resulted in increased cell proliferation and decreased differentiation in lung adenocarcinomas [13]. Inhibition of SBP1 by siRNA effectively increased cell motility, promoted cell proliferation, and inhibited apoptosis in hepatocellular carcinoma cell lines [26]. Conversely, ectopic SBP1 expression in colorectal cancer cells resulted in inhibition of cancer cell proliferation and the induction of apoptosis, attenuated cancer cell migration in vitro, and significantly inhibited cancer cell growth in nude mice [20]. These findings clearly demonstrated a likely tumor suppressor function of SBP1, although determining the underlying molecular mechanisms requires further investigation.

Inverse regulation and interaction between SBP1 and GPx1
We recently reported that ectopic expression of SBP1 was sufficient to cause an approximately 50% reduction in the activity of the GPx-1 selenoprotein in human HCT116 colon cancer cells without affecting GPx1 mRNA and protein levels [30]. However, increased expression of GPx1, achieved either by transfection of a GPx1 expression construct or by supplementing the media with selenium, resulted in the significant reduction of SBP1 protein and mRNA levels. Selenium titration studies, either in the presence or absence of GPx1, established that the opposing regulation of these proteins was not due to a simple competition for available selenium, and this conclusion was supported by co-immunoprecipitation studies that indicated that SBP1 and GPx1 formed a physical interaction. These results were extended to mice which indicated that increasing GPx1 levels by dietary selenium supplementation resulted in a decline in SBP1 levels in colonic and duodenal epithelial cells [30]. These studies were extended by the work of others in which it was shown that SBP1 and GPX1 formed nuclear bodies and also co-localized under oxidative stress, and that decreased SBP1 was associated with increased GPX1 activity and correlated with vascular invasion in freshly isolated clinical hepatocellular cancer tissues [26]. These results were similar to our most recent data indicating that there is an inverse association between SBP1 and GPx1 levels in human colon (Yang et al., not published) and prostate, as well as the demonstration of an association between higher GPx1 levels and clinical Gleason grade of prostate cancer tissues [31]. These data have collectively demonstrated both an inverse regulation and physical interaction between the representatives of two distinct classes of selenoproteins, each implicated in cancer etiology.

Conclusion
SBP1 is expressed in normal tissues, but its levels are reduced in multiple types of cancer. Reduced levels of SBP1 likely result from both epigenetic and posttranscriptional alterations. SBP1 is inversely regulated and interacts with GPx1, and these effects might be mediated, at least in part, by selenium. Clinically, the reduced expression SBP1 is linked to poor survival of cancer patients (Figure 1). Therefore, SBP1 SBP1 expression may
be developed as an indicator for the monitoring of carcinogenesis and progression, as well as a biomarker for the prediction of cancer risk and clinical prognosis.

**Abbreviations**

SBP1: Selenium-binding protein 1; GPX1: Glutathione peroxidase 1; BE: Barrett’s esophagus.

**Competing interests**

Authors declare no conflict of interest.

**Authors’ contribution**

WY and AD drafted the manuscript. Both authors read and approved the final manuscript.

**Acknowledgements**

We would like to thank Dr. Wenfeng Fang (Sun yat-sen University Cancer Institute, Guangzhou, China), Dr. Tina Li (University of California, Davis, CA), Dr. Nicole Pohl (University of Illinois at Chicago, Chicago, IL) and Dr. Xiuli Bi (Liaoning University, Shenyang, China) for their contribution to this work. This work is sponsored in part by the grant from the Nature Science Foundation of China (grant # 81272251 and 91229115 to W. Yang), the startup fund from Xinxiang Medical University (to W. Yang), China and by a grant from the National Institutes of Health (Grant # RO1CA127943 to A.M. Diamond).

We would like to thank Dr. Wenfeng Fang (Sun Yat-Sen University Cancer Institute, Guangzhou, China) for their contribution to this work. This work is sponsored in part by the grant from the Nature Science Foundation of China (grant # 81272251 and 91229115 to W. Yang), the startup fund from Xinxiang Medical University (to W. Yang), China and by a grant from the National Institutes of Health (Grant # RO1CA127943 to A.M. Diamond).

Received: 15 December 2012 Accepted: 2 February 2013

Published: 1 March 2013

**References**

1. Group, KDR: Epidemiologic studies on the etiologic relationship of selenium and Keshan disease. *Clin Med J (Engl)* 1979, 92:477–482.

2. Bellinger FP, Raman AV, Reeves MA, Berry MJ: Regulation and function of selenoproteins in human disease. *Biochem J* 2009, 422:11–22.

3. Greenwald P, Anderson D, Nelson SA, Taylor PR: Clinical trials of vitamin and mineral supplements for cancer prevention. *Am J Clin Nutr* 2007, 85:3145–3175.

4. Behne D, Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN: Characterization of mammalian selenoproteomes. *Science* 2003, 300:1439–1443.

5. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN: Characterization of mammalian selenoproteomes. *Science* 2003, 300:1439–1443.

6. Behne D, Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN: Characterization of mammalian selenoproteomes. *Science* 2003, 300:1439–1443.

7. Greenwald P, Anderson D, Nelson SA, Taylor PR: Clinical trials of vitamin and mineral supplements for cancer prevention. *Am J Clin Nutr* 2007, 85:3145–3175.

8. Behne D, Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN: Characterization of mammalian selenoproteomes. *Science* 2003, 300:1439–1443.

9. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN: Characterization of mammalian selenoproteomes. *Science* 2003, 300:1439–1443.

10. Bansal MP, Oborn CJ, Danielson KG, Medina D: Evidence for two selenium-binding proteins distinct from glutathione peroxidase in mouse liver. *Carcinogenesis* 1989, 10:541–546.

11. Chang PW, Tsiu SK, Liew C, Lee CC, Waye MM, Fung KP: Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. *J Cell Biochem* 1997, 64:217–224.

12. Poirat A, Sagky Y, Elazar Z: A S6-Kda Selenium-binding Protein Participates in Intra-Golgi Protein Transport. *J Biol Chem* 2000, 275:14657–14665.

13. Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano TJ, Oringer MB, Hanash SM, Beer DG: Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. *J Pathol* 2004, 202:321–329.

14. Li T, Yang W, Li M, Byun DS, Tong C, Nasser S, Zhuang M, Arango D, Mariadason JM, Augenlicht LH: Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. *MoL Nutr Food Res* 2008, 52:1289–1299.

15. Scortegagna M, Martin RJ, Kladney RD, Neumann RG, Arbeiten JM: Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. *Cancer Res* 2009, 69:2638–2646.

16. Jeong J-Y, Wang Y, Syktowski AJ: Human selenium binding protein-1 (HSBP1) interacts with VDUI in a selenium-dependent manner. *Biochem Biophys Res Commun* 2009, 379:583–588.

17. Pasl HI, Liu Z, Wall A, Bueno R, Land S, Lott D, Siddiq F, Lonardo F, Carbone M, Draghici S: Gene expression profiles predict survival and progression of pleural mesothelioma. *Clin Cancer Res* 2004, 10:8489–859.

18. Huang KC, Park DC, Ng SK, Lee JY, Li X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW: Selenium binding protein 1 in ovarian cancer. *Int J Cancer* 2006, 118:2433–2440.

19. Kim H, Kang HJ, You KT, Kim SH, Lee KY, Kim TI, Kim C, Song SY, Kim HJ, Lee C, Kim H: Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. *Proteomics* 2006, 6:3466–3476.

20. Poh NM, Tong C, Fang W, Bi X, Li T, Yang W: Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. *PLoS One* 2009, 4:e7774.

21. Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, Lin J, Giordano TJ, Oringer MB, Beer DG, Chang AC: Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. *Clin Cancer Res* 2010, 16:2009–2020.

22. Xia YJ, Ma YY, He XJ, Wang HJ, Ye ZY, Tao HQ: Suppression of selenium-binding protein 1 in gastric cancer is associated with poor survival. *Hum Pathol* 2011, 42:1620–1628.

23. Zhang L, Dong WG, Lin J: Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma. *Med Oncol* 2011, 28:481–487.

24. Zhang J, Zhan N, Dong WG: Altered expression of selenium-binding protein 1 in gastric carcinoma and precursor lesions. *Med Oncol* 2010, 28:351–357.

25. Zhang Z, Zhang C, Wang X, Liu F, Sung CJ, Quddus MR, Lawrence WD: The expression of selenium-binding protein 1 is decreased in uterine leiomyoma. *Diagn Pathol* 2010, 5:90.

26. Huang C, Ding G, Gu C, Zhou J, Kuang M, Ji Y, He Y, Kondo T, Fan J: Decreased selenium-binding protein 1 enhances glutathione peroxidase 1 activity and downregulates HIF-1alpha to promote hepatocellular carcinoma invasiveness. *Clin Cancer Res* 2012, 18:3042–3053.

27. Stasso DI, Volpe MG, Colonna G, Nazzaro M, Polimeno M, Scala S, Castigllo G, Costantini S: A possible predictive marker of progression for hepatocellular carcinoma. *Oncol Lett* 2012, 3:247–251.

28. Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath SM, Liu D: Recent advances and novel agents for gastrointestinal stromal tumor (GIST). *J Hematol Oncol* 2012, 5:23.

29. Lamba G, Gupta R, Lee R, Ambrale S, Liu D: Current management and prognostic features for gastrointestinal stromal tumor (GIST). *Experimental Hematology & Oncology* 2012, 1:14.

30. Fang W, Goldberg ML, Poh NM, Bi X, Tong C, Xiong B, Koh TJ, Diamond AM, Yang W: Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 seleniumprotein. *Carcinogenesis* 2010, 31:360–366.

31. Jerome-Morais A, Wright ME, Liu R, Yang W, Jackson MJ, Combs GF, Jr, Diamond AM: Inverse association between glutathione peroxidase activity and both selenium-binding protein 1 levels and gleason score in human prostate tissue. *Prostate* 2012, 72:1006–1012.

doi:10.1186/2050-7771-1-15

Cite this article as: Yang and Diamond: Selenium-binding protein 1 as a tumor suppressor and a prognostic indicator of clinical outcome. *Biomarker Research* 2013, 1:15.